In preclinical studies, the classical components of cell-cycle progression and DNA-damage repair, such as ATM, DNA-PKcs, ATR, CHK1, CHK2 and WEE1, have shown to be very promising targets for radiosensitizing tumor cells by applying small-molecule inhibitors [89], [90], [91], [92]. The gene discussed is CHEK2; the disease is neoplasm.